First, the naming. Why "GLP-3" is — and isn't — accurate.
Retatrutide is Eli Lilly's investigational obesity therapy. Biologically, it is a triple receptor agonist: a single molecule engineered to activate three pathways at once — GLP-1 (the one in Ozempic), GIP (the second one in Mounjaro/tirzepatide), and glucagon (a new axis for obesity medicine).
The internet has adopted the shorthand GLP-3. Scientifically, it is imprecise. It is not a third-generation GLP. It is a triple agonist. But the label has stuck because the cultural conversation needs a clean version-number — and "retatrutide" does not trend well on TikTok.
We use both here, plainly. The pharmacology is the pharmacology whatever you call it.
What it is: Retatrutide — Eli Lilly triple agonist (GLP-1 + GIP + glucagon).
Where it is: Phase 3. Primary endpoint readout reported Q1 2026. Additional Phase 3 trials reading out across 2026.
Headline number: Average weight loss of ~71.2 lbs (about 29% of body weight) at the highest dose in the primary obesity trial.
FDA status: Not approved. Filing anticipated following completion of the full Phase 3 package.
Source: Eli Lilly investor update, Q1 2026.
The Phase 3 data, in one page.
Lilly's TRIUMPH trial program tested retatrutide in adults with obesity at multiple dose tiers, compared to placebo, with weight reduction as the primary endpoint over approximately 72 weeks of treatment.
In the primary obesity readout reported in Q1 2026, participants on the highest retatrutide dose lost an average of approximately 29% of baseline body weight — roughly 71.2 pounds for the average participant. For comparison, semaglutide (Ozempic/Wegovy) averages about 15% body-weight loss in STEP trials, and tirzepatide (Mounjaro/Zepbound) averages about 22% in SURMOUNT trials. Retatrutide is, on these numbers, nearly double Ozempic's effect.
A note of discipline: these are average numbers across treated populations. Individual responses vary, discontinuation rates matter, and long-term maintenance data — the same question that now haunts semaglutide — is not yet available for retatrutide. Phase 3 is where drugs look their best. Real-world performance after approval is where reality lives.
The FDA timeline, realistically.
At time of writing (Q2 2026), retatrutide is not FDA-approved. Lilly has not yet submitted a New Drug Application for the obesity indication. Typical sequence from here:
- Remainder of the Phase 3 program reads out across 2026 (Lilly has referenced roughly seven additional trials in the TRIUMPH family).
- NDA submission follows completion of the core Phase 3 package.
- FDA review — standard 10 months, priority 6 months — may be accelerated given the public interest.
- Earliest plausible US approval: late 2026 to 2027, depending on filing timing.
Drugs.com's retatrutide pipeline page tracks these steps in close to real time and is a reasonable lay-reference.
Phase 3 is where drugs look their best. Real-world performance after approval is where reality lives.
If you're currently on Ozempic, what does this mean?
Three honest answers, all at once:
01 · Nothing changes today
Retatrutide is not available. You cannot switch to it. The product sold online under similar names is unregulated research chemical, not the Lilly compound, and carries the risks of any grey-market injectable.
02 · The landscape expands, not contracts
The narrative that GLP-1s are "fading" because of side-effect discourse is not supported by the trial data. With retatrutide at 29% and orforglipron (oral GLP-1) filing in 2026, the category is broadening. For patients, that means more options, more physician choice, and more pressure on payers.
03 · The rebound question doesn't go away
Any drug that drives weight loss through appetite suppression and gastric-emptying delay will, when discontinued, be followed by some degree of physiological rebound. The STEP-1 extension (Wilding et al., 2022) showed this for semaglutide. The mechanism is the drug, not the molecule. This is why the post-drug protocol conversation — what to do when you come off, or microdose, or transition — matters regardless of which GLP-era drug you are on.
Ozemback does not recommend or support obtaining retatrutide from unregulated sources. Compounds sold online as "retatrutide" are research chemicals of unverified purity, dose accuracy, and safety. Several telehealth and compounded-peptide markets will almost certainly add retatrutide-mimicking products before Lilly's FDA approval. Do not be in that first wave.
What to actually do, now.
- If you're on a GLP-1 and it's working: stay on your protocol. Do not change medications based on a press release.
- If you're coming off: the post-drug biology (rebound, food noise, muscle loss) applies the same way. Read the starter guide. Make a plan before your last dose.
- If you're watching retatrutide: bookmark Drugs.com's pipeline page and the Lilly investor relations site for primary-source updates. Everything else downstream is a rewrite of those.
- If you're tempted by grey-market retatrutide: don't. Wait. The approved version is a year or two away, not a decade.
We will update this piece whenever a material Phase 3 readout lands or Lilly files. Join the list to receive the 2026 series — Vol. 01 starter guide here — and the GLP-3 Watch when it ships.